These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 21342141

  • 1. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
    Kučukalić-Selimović E, Valjevac A, Hadžović-Džuvo A, Skopljak-Beganović A, Alimanovic-Alagić R, Brković A.
    Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
    [Abstract] [Full Text] [Related]

  • 2. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 3. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
    [Abstract] [Full Text] [Related]

  • 5. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 6. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 8. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
    Bruyère O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C, Detilleux J, Reginster JY.
    Osteoporos Int; 2010 Jun; 21(6):1031-6. PubMed ID: 19813043
    [Abstract] [Full Text] [Related]

  • 9. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 10. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Nov; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 11. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
    Iwamoto J, Uzawa M, Sato Y, Takeda T, Matsumoto H.
    J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.
    J Bone Miner Metab; 2009 Mar; 27(4):471-8. PubMed ID: 19343272
    [Abstract] [Full Text] [Related]

  • 13. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [Abstract] [Full Text] [Related]

  • 14. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 15. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
    Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R, EUROFORS Study Group.
    Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
    [Abstract] [Full Text] [Related]

  • 16. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A, Hannon R, Eastell R.
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [Abstract] [Full Text] [Related]

  • 17. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
    Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, Yao X, Gu G, Hao Y, Li Z, Zhao Y, Li W, Yang J, Zhao X, Shi D, Fuerst T, Lu Y, Li H, Zhang X, Li C, Zhao J, Wu Q, Zhao SJ.
    Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
    [Abstract] [Full Text] [Related]

  • 18. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 19. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 20. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Clemmesen B, Christiansen C.
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.